Dr. Nabarun Dasgupta Profile picture
Jun 8, 2021 32 tweets 24 min read Read on X
We are unveiling new findings about MME/day calcs for #opioids @US_FDA Workshop today. Live blogged in thread below.

Lab notebook, code, equations:
opioiddata.org/studies/equati…
With @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey
#epitwitter #RxEpi #medtwitter
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey Apologies in advance... this is experimental live blogging... sometimes twitter scrambles images on long threads
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey 14 states impose limits on opioid dosage that can be prescribed, ranging from 30 MME to a 120 MME daily maximum. Also third-party payers (insurance, @CMSgov). Analysis by @coreysdavis @amyamnesia of @networkforphl
onlinelibrary.wiley.com/doi/10.1111/ad…
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @CMSGov @coreysdavis @amyamnesia @networkforphl Is this a "high dose" patient?
Rx1: 30 mg BID oxycodone ER, 30 days (#60) = 2,700mg
Rx2: 5mg oxycodone IR ~BID prn for first 7 days (#14) = 105mg
assume 1.5x conversion
Total: 2,805mg
Would you believe that some definitions say YES, and some definitions say NO? Srsly. 👇
@US_FDA @chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @CMSGov @coreysdavis @amyamnesia @networkforphl Here's our revelation from reviewing the evidence base cited in the 2016 CDC Guideline: There are FOUR (4) different ways to calculate daily MME, not even considering conversion tables. The scenario above would yield:
31.2 MME/day
75.8 MME/day
93.5 MME/day
105 MME/day
How do they differ? The denominator. It is the "day" part of "MME per day" that's been ignored.

How do you measure, measure a day in the life of a patient?

Definition 1/4: Total Days Supply
Denominator is sum of days supply

2805mg/37days = 75.8 MME/day

Example: pubmed.ncbi.nlm.nih.gov/18574361/
Definition 2/4: On-therapy Days
Denominator is calendar days, counting overlap days once

2805mg/30days = 93.5 MME/day

Example: ncbi.nlm.nih.gov/pmc/articles/P…
Definition 3/4: Fixed Observation Window
Denominator is fixed at 90days for all patients

2805mg/90days = 31.2 MME/day

Example: ncbi.nlm.nih.gov/pmc/articles/P…
Definition 4/4: Maximum Daily Dose
The "CDC Method" ignores dates and days supply for max single-day exposure, used in the CDC Opioid Guideline mobile app.

max = 90mg+15mg = 105 MME/day

Example: academic.oup.com/painmedicine/a…
For reals, does any of this really matter?
Stay tuned: Subtle choices make huge differences.
A Controlled Experiment that mimics an observational policy/intervention evaluation.

Compare 2 places to see which has more "high dose" patients.

Same dataset, same conversion factors.

The ONLY source of variation comes from the4 definitions ofdaily MME.
Methods. PDMP data for 3Q2018.

9,436,640 opioid analgesic prescriptions
California n=5,677,277
Florida n=3,759,363

3,916,461 unique adult residents
California n=2,430,870 (7.9 per 100 residents)
Florida n=1,485,591 (8.7 per 100 residents)
3-fold difference in which patients are considered high dose between D1 and D4. Both are described in published papers as the "CDC Method": 5.9% vs. 14.2% (FL)

Arbitrary definition choice impacts hundreds of thousands of patients with painful conditions.
4 policy/intervention evaluations on the SAME DATA with the SAME CONVERSION TABLES wouldn't agree how many more "high dose" patients were in FL: 64%, 59%, 84%, or 39% more
Any of these means or medians could have been justified scientifically. SAME DATA but 8 different results. See? Subtle choices have huge consequences.
Would we say that doses are similar (1 mg difference) but lots more "high dose" patients in FL?
or
FL has a bit more "high dose" patients, but they are getting A LOT more (13 mg)?

Imma a say it again: Subtle choices have huge consequences in what we infer.
Why is this happening? Overlapping prescription days supply has a lot to do with it.

Epi/stats folks, beware. Changes in US prescribing patterns mean that certain definitions (D1) will attenuate intervention effects over time!
If you shift the “high dose” threshold from 90.9 to 90.0, you increase the number of “high dose” patients by 15.4% (CI: 15.2%, 15.7%).
If an insurance company and physician use 90.0 vs. 90.9, they would disagree on "high dose" status in 1 out of every 30 patients with D4.
Which definition to use? I like D2 in general, but D3 is good for long-term use because it is more robust to misclassification. Do not use D1. If toxicity is short-term in opioid naive patients, D4 could possibly maybe be sorta acceptable.
We are building a tool for research decisions. We need beta testers! DM or email me if you're interested.
"And while everyone debates whether the MME limit was the right thing to do, we are forced to live by it, because medical personnel treat guidelines as mandates. So we wait. And we suffer. And we hope it will all get sorted so we can get the care we need.” Liz Joniak-Grant
Or, as one patient put it to me when I showed them the results: "It's f--king arithmetic. Get it right."
Limitations of our study are here. We don't recommend using these conversion factors naively for clinical decisions, either.
If a study doesn't sufficiently define how they calculated MME per day, I don't read the results.
These results will be published in @ClinJrnlPain (Clinical Journal of Pain) in a couple of weeks. Paper has been accepted and proofs are being typeset one last round. And yes, it'll be free open access. In the meantime, check out OpioidData.org for details.
Thanks to our talented illustrator-in-residence @brittainpeck for breathing visual life into technical medical concepts. Feel free to use any images or slides.
In closing, if you are a researcher, please please please state your definition. Feel free to reuse our equations or slides. In this way, we can be allied with patients to reduce the most harm, with the best information.
Key message: Subtle choices have big consequences.
We offer proof that daily MME is not a standardized clinical metric.
Let us know what you think! Thanks for reading.
Follow co-authors
@chris_delcher @yanningwang @AlanKinlaw @ToskaCooper @BrookeChidgey @Jungjun_Bae

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dr. Nabarun Dasgupta

Dr. Nabarun Dasgupta Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @nabarund

Jun 7
Let's bring some science into all this talk about #medetomidine. 🧵

TLDR: Expect unexpected sedation.

We predicted it would soon emerge in illicit supply, and @US_FDA agreed, and so we have this grant to investigate its pharmacology, etc. @nanopharmNC

fda.gov/science-resear…
We first observed #medetomidine in NC in a sample collected in October 2022, in Raleigh. Combined with xylazine, and traces of fentanyl and meth. @LunaJBear
streetsafe.supply/results/p/3004…
If you've seen me present in the last year, #medetomidine has been sitting on our team's Watch List (slide 52) for awhile now.
cdr.lib.unc.edu/concern/schola…
Read 24 tweets
Sep 9, 2023
1 🚨Attention please: Turns out #xylazine is a kappa opioid. This validates experience from frontline folks and PWUD. Fresh science from collaborators @nanopharmNC @MadiganLBedard @zenbrainest
Pre-print:
Public health 🧵 below
#TwitteRx #harmreductionbiorxiv.org/content/10.110…
Check out @nanopharmNC's explainer on the lab science. I'll breakdown the #publichealth implications.
@nanopharmNC Basic pharmacology. Mu is the opioid receptor in the brain we usually talk about when we say “opioid” – but there are others. Kappa is less popular, but still very much an opioid receptor. HOWEVER, it’s NOT canonically linked to opioid euphoria.

sites.tufts.edu/opioidpeptides…
Image
Read 18 tweets
May 22, 2023
Let's talk #nalmefene for OD reversal, an old generic drug in new expensive clothes. FDA approved Rx-only nasal spray today. Will this help prevent overdose deaths in the fentanyl-xylazine-strongbenzo era?

🧵👇

fda.gov/news-events/pr…
Nalmefene was developed in the 1980s by erstwhile Key Pharma in Miami, with help from scientists at @UVA
europepmc.org/article/med/39…
It was marketed as an injectable by Baxter Pharma as Revex for alcohol dependence, initially approved in April 1995 and "discontinued on May 21, 2008, for business reasons."

federalregister.gov/documents/2017…
Read 21 tweets
Apr 12, 2023
Based on our lab data, I reckon #xylazine shows up in the drug supply 5 specific ways:
🧵👇
1. Veterinary diversion is rare, niche, and localized to interconnected Caribbean communities:

Philly


Puerto Rico
link.springer.com/article/10.118…
2. Most commonly... Fentanyl and #xylazine in combo, about 3:1.

We don't see xylazine-related synthesis impurities but do see fentanyl impurities, so our hypothesis is that xyl is being added intentionally in pure form.
Example from Lexington NC: streetsafe.supply/results/p/3003…
Read 14 tweets
Feb 15, 2023
Y'all ready for this? 🍿👊
#NarcanAdCom about to pop off
Use this # to follow today's updates

CONCEPT
The culmination of 2 decades of advocacy to make naloxone OTC

REALITY
2 decades of advocacy erased by overdose crisis profiteers $EBS

Right out the gate, FDA frames this as a solution for saving kids from overdose. Guess that’s why there are so many pediatric anesthesiologists on the AdCom
In the review of the history FDA forgets to credit the people (like Dan Bigg) who invented the intervention
Read 53 tweets
Sep 23, 2022
🚨 Something huge happened today. 🚨

@US_FDA @DrCaliff_FDA listened to harm reduction programs and made it infinitely easier to purchase #naloxone in bulk. With 100,000+ overdose deaths each year, we need BIG solutions.

w/@RemedyAlliance @ejwheeler9 @coreysdavis
🧵 1/26
@US_FDA @DrCaliff_FDA @RemedyAlliance @ejwheeler9 @coreysdavis The FDA Guidance provides clear federal support for bulk purchase and distribution of naloxone to meet one of the biggest public health challenges of our times.

Full text via link below, but let's break it down.


2/26
@US_FDA @DrCaliff_FDA @RemedyAlliance @ejwheeler9 @coreysdavis This is a watershed moment. Along with low-cost naloxone available through @RemedyAlliance and state standing orders, this Guidance establishes a trifecta of innovations that will help rapidly scale up naloxone distribution.
3/26
Read 33 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(